Advancing a class on top of statins
World Class Leadership
Board of Directors
Charles Bisgaier
Charles Bisgaier

PhD

Dr. Bisgaier serves as our Chairman and Chief Scientific Officer. From 1990 to 1998, Dr. Bisgaier was an Associate Research Fellow in the Department of Vascular and Cardiac Disease at Warner-Lambert/Parke-Davis. There he participated in the discovery and/or development of gemfibrozil (LOPID®), atorvastatin (LIPITOR®) and gemcabene (AKA CI-1027 and PD 72953). Subsequently, Dr. Bisgaier co-founded the first Esperion Therapeutics (1998- 2004), which was then acquired by Pfizer. At Pfizer he then served as the Senior Director of Pharmacology at the Esperion Division of Pfizer Global Research and Development. Notably, he was a major influence in the discovery, research and/or development of many small molecules with potential utility for metabolic syndrome including ETC-1002 (AKA ESP 55016) which was licensed by the new Esperion (NASDAQ: ESPR) from Pfizer, as well as HDL-therapy product candidates, such as ApoA-I Milano (ETC-216) which was also licensed by The Medicines Company (NASDAQ: MDCO) from Pfizer. After Pfizer, he served as a Company Director, Board Member and President of Pipex Pharmaceuticals (2006-2008, currently known as Synthetic Biologics, NYSE: SYN), a specialty pharmaceutical company focused on developing fibrotic and neurological disease therapies, that included a treatment for Relapsing Remitting Multiple Sclerosis. Both Pipex Pharmaceuticals and the first Esperion Therapeutics became public companies through a reverse-merger and an initial public offering (IPO), respectively during Dr. Bisgaier's tenure. He is also a co-founder of Michigan Life Therapeutics (predecessor to Gemphire) and Michigan Life Ventures. In addition, he is currently a Board member at Hygieia, Inc., a company that has developed a novel handheld medical device to assist diabetics to determine appropriate dosage when self-administering insulin, and a Board member at BioSavita Inc., a company that has developed a novel platform technology for protein expression in yeast. He also has served as a Board member (2009-2014) and President and CEO (2010-2011) of ProNAi Therapeutics (NASDAQ: DNAI). Currently, Dr. Bisgaier is also an Adjunct Associate Professor of Pharmacology at the University of Michigan. He received a B.A. in Biology from the State University College at Oneonta, NY (1974), and a M.S.(1977) and Ph.D. (1981) in biochemistry from George Washington University, Washington, D.C. After receiving his doctorate, he studied lipoprotein metabolism within the Specialized Center of Research (SCOR) for atherosclerosis at Columbia University College of Physicians and Surgeons, NY.

Steve Gullans
Steve Gullans

PhD

Dr. Gullans has served as a member of our board of directors since April 2016. He is currently Managing Director at Excel Venture Management (Excel), a Boston-based venture capital firm which he co-founded and where he has been employed since February 2008. At Excel, he focuses on investing in life science technology companies with a particular interest in disruptive platforms that can impact multiple industries. Prior to Excel, Dr. Gullans co-founded RxGen, Inc., a pharmaceutical services company where he served as chief executive officer from January 2004 to February 2008. Dr. Gullans is currently a director at Molecular Templates, Inc., a private biotechnology company, Cleveland HeartLab, Inc., a private cardiovascular testing company, and N-of-One, Inc., an oncology diagnostics company. He was previously a board member of Activate Networks, Inc. which was acquired by Decision Resource Group, BioTrove, Inc. which was acquired by Life Technologies Corporation, Biocius Life Sciences, Inc. which was acquired by Agilent Technologies Inc., nanoMR Inc. which was acquired by DNA Electronics Ltd and Tetraphase Pharmaceuticals, Inc. which went public in 2013. Dr. Gullans was a faculty member at Harvard Medical School and Brigham and Women’s Hospital for almost 20 years. Dr. Gullans holds a B.S. from Union College and a Ph. D from Duke University.

Kent Hawryluk
Kent Hawryluk

MBA

Mr. Hawryluk has served as a member of our board of directors since February 2015. He serves as Co-Founder/Chief Business Officer of Avidity NanoMedicines which is a pioneer in precision nanomedicines and also Co-Founder/CEO of MB2 which is a clinical development stage company focused on diabetes and obesity. Previously, Mr. Hawryluk was Co-Founder/Chief Business Officer of Marcadia Biotech, which was acquired by Roche. He also currently serves as partner of Twilight Venture Partners, a private seed- and early-stage life science venture fund. He was a founding partner of JEGI Capital, a venture capital fund co-sponsored by GE Capital that launched in 2000. Mr. Hawryluk holds a Bachelor’s degree from Princeton University, an MBA from Kellogg School of Management at Northwestern University, and a M.Sc. in Biology from Indiana University-Purdue University Indianapolis.

Kenneth Kousky
Kenneth W. Kousky

MEcon, CISSP, CISA, CGEIT, CRISC

Mr. Kousky has served as a member of our board of directors since March 2015. Mr. Kousky serves as the CEO of the Mid-Michigan Innovation Center, a privately funded, non-profit business incubator and also the President/CEO of IP3, Inc., an information security consulting firm. Prior to these, Mr. Kousky founded an IT services company, Wave Technologies (NASDAQ:WAVT), where he guided his vision from formation through an IPO. Also, Mr. Kousky is a founding member and Executive Director of the BlueWater Angels Investment Network, a Michigan-based funding network that reviews more than 100 potential businesses annually. He established Washington University's graduate program in Telecommunication Management and also lectured at Saginaw Valley State University, Washington University and at the Wharton School of Business, University of Pennsylvania. Mr. Kousky serves on several advisory boards including: Michigan Sugar Company; MiQuest; RetroSense Therapeutics; Michigan Pre-Seed Fund 2.0 Investment Review Committee; Saginaw Public Schools Foundation; Saginaw Valley State University Board of Fellows and SVSU’s College of Business and Management; Duperon Corporation; Foodjunky; Salare Security; and prior Founder and Board Member of Bravo:Smart Web Design. Mr. Kousky holds a Bachelor’s degree in Economics and Urban Studies from Washington University, and a Master’s degree in Economics from University of Pennsylvania.

Pedro Lichtinger
Pedro Lichtinger

MBA

Mr. Lichtinger has served as a member of our board of directors since December 2015. Mr. Lichtinger serves as President and Chief Executive Officer and a Director of Asterias Biotherapeutics, a public company with a focus on Neurology and Oncology. Prior to joining Asterias Mr. Lichtinger served as President, Chief Executive Officer and a director of Optimer Pharmaceuticals, Inc. a company focused on the hospital antibacterial market. Mr. Lichtinger previously served as an executive of Pfizer Inc. in a number of different roles including as President of Pfizer's Global Primary Care Unit, Area President, Europe, President, Global Animal Health and Regional President Europe Animal Health. Before joining Pfizer, Mr. Lichtinger was an executive of Smith Kline Beecham, last serving as Senior Vice-President Europe Animal Health. Mr. Lichtinger serves as a director of Sanfer de Mexico, a leading Mexican pharmaceutical company. Pedro also serves on the National Board of Governors of Boys and Girls Clubs of America and is a Director of the Brazil Foundation. Mr. Lichtinger holds an MBA degree from the Wharton School of Business and an Engineering degree from the National University of Mexico.

Andrew Sassine
Andrew Sassine

MBA

Mr. Sassine has served as a member of our board of directors since May 2015. Mr. Sassine served in various positions at Fidelity Investments from 1999 to 2012, rising to the position of Portfolio Manager. Prior to joining Fidelity, he served as a vice president in the Acquisition Finance Group at Fleet National Bank. Mr. Sassine serves on the board of directors of two other public companies: iCAD, Inc. (NASDAQ:ICAD), an industry leading provider of advanced image analysis, workflow solutions and radiation therapy for the early detection and treatment of cancer; and MYnd Analytics, Inc. (OTC: CNSO), a predictive analytics company that provides objective clinical decision support to mental health care provider for the personalized treatment of behavioral disorders. Mr. Sassine also serves on the board of directors of two private companies: Freedom Meditech, Inc., a medical device company focused on the development and commercialization of first-to-market non-invasive ophthalmic medical devices that can screen for diabetes up to six years prior to the onset of the disease; and Comhear Inc., a digital audio software and device company, where he is also the Chairman of the Board. Mr. Sassine has been a member of the Henry B. Tippie College of Business, University of Iowa Board of Advisors since 2009 and served on the Board of Trustees at the Clarke Schools for Hearing and Speech from 2009 through 2014. Mr. Sassine holds a Bachelor of Arts degree at the University of Iowa and an MBA from the Wharton School at the University of Pennsylvania.